Skip to product information
1 of 1

PE Mouse Anti-Human CD110 Antibody (S-3014)

PE Mouse Anti-Human CD110 Antibody (S-3014)

Catalog Number: S0B5840 Application: FCM Reactivity: Human Conjugation: PE Brand: Starter
Price:
Regular price $288.00 SGD
Regular price Sale price $288.00 SGD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Mouse
Antigen CD110
Synonyms Thrombopoietin receptor; TPO-R; Myeloproliferative leukemia protein; Proto-oncogene c-Mpl; TPOR; MPL
Location Cell membrane
Accession P40238
Clone Number S-3014
Antibody Type Mouse mAb
Isotype IgG2a,k
Application FCM
Reactivity Hu
Positive Sample human peripheral blood cells
Purification Protein A
Concentration 0.2 mg/ml
Conjugation PE
Physical Appearance Liquid
Storage Buffer

PBS, 1% BSA, 0.3% Proclin 300

Stability & Storage

12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution


application dilution species
FCM 5μl per million cells in 100μl volume Hu

Background

CD110, also known as thrombopoietin receptor (TPOR) or MPL (myeloproliferative leukemia protein), is a 635-amino-acid, single-pass type I transmembrane glycoprotein belonging to the hematopoietic cytokine receptor superfamily, whose extracellular N-terminal region binds thrombopoietin (TPO) with high affinity to activate JAK2/STAT, MAPK and PI3K-AKT signaling cascades that drive megakaryocyte proliferation, differentiation and platelet production, while its cytoplasmic C-terminal tail contains critical motifs for internalization and negative feedback regulation; physiologically expressed on hematopoietic stem cells, megakaryocytes, platelets and endothelial cells, CD110 is essential for steady-state and stress hematopoiesis, and genetic alterations—such as MPL W515L/K activating mutations or CALR exon 9 mutations that create neomorphic ligand binding—lead to ligand-independent signaling, constitutive activation and the development of myeloproliferative neoplasms, making CD110 a key diagnostic marker and therapeutic target for small-molecule JAK inhibitors and TPO receptor agonists/antagonists in thrombocytopenias and myelofibrosis.

Picture

FC

Flow cytometric analysis of Human CD110 expression on human peripheral blood cells. Human peripheral blood cells were stained with either PE Mouse IgG2a, κ Isotype Control (Black line histogram) or SDT PE Mouse Anti-Human CD110 Antibody (Red line histogram) at 5 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.